Popular search terms:
Search Results
102 results found-
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.us/news -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.us/news/csl-seqirus-presents-data-at-idweek-2024 -
CSL Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.
https://www.cslseqirus.us/products -
CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States.
https://www.cslseqirus.us/news/csl-seqirus-begins-shipping-its-portfolio-of-influenza-vaccines-for-the-2024-25-flu-season -
Results from real-world evidence (RWE) studies to be presented at OPTIONS XII show the effectiveness of cell-based and MF59® adjuvanted influenza vaccines.
https://www.cslseqirus.us/news/csl-seqirus-presents-real-world-evidence-at-options-xii-conference -
Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.
https://www.cslseqirus.us/expertise/influenza -
Results of the first season of a randomized study showed adjuvanted and high-dose influenza vaccines did not differ in effectiveness against PCR-confirmed influenza.
https://www.cslseqirus.us/news/new-data-presented-at-idweek-2024 -
CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.cslseqirus.us/expertise -
Biomedical Advanced Research and Development Authority (BARDA) and CSL Seqirus will expand their reserves of MF59® adjuvant to the equivalent of 40 million doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
https://www.cslseqirus.us/news/csl-seqirus-announces-fifth-barda-award-in-response-to-avian-influenza -
CSL Seqirus has received a Biomedical Advanced Research and Development Authority (BARDA) award to complete the fill and finish process for additional pre-pandemic vaccines to further support the U.S. government’s outbreak and preparedness response.
https://www.cslseqirus.us/news/csl-seqirus-announces-sixth-barda-award-in-response-to-avian-influenza